On-demand video webcast now available here TAMPA, FL / ACCESS Newswire / February 19, 2025 / TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 registration-stage immune-oncology company dev ...

Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. See why REGN stock is a top ...

Over 230 patients enrolled in potential registration-enabling trial in 1L HLA-A2-negative MUM, and median PFS readout targeted by year-end 2025 95 patients enrolled ...

Exelixis, Inc. EXEL reported better-than-expected fourth-quarter results. EXEL recorded earnings of 55 cents per share, which beat the Zacks Consensus Estimate of 51 cents. The company registered ...

The company's stock recently dropped 9% following a disappointing update on the vaccine business in China, further emphasizing the risks of overdependence on one blockbuster drug. Keytruda ...

The quote below is from a Wall Street Journal interview ... Unfortunately, investors seeking shelter in healthcare stocks for dividend growth and capital gains have been unable to outperform ...

Merck MRK reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.72, which beat the Zacks Consensus Estimate of $1.69. In the year-ago period, management reported adjusted EPS of 3 cents ...

Fourth-quarter revenue was boosted by a 21% rise to $7.84 billion in sales of the blockbuster cancer drug Keytruda. Merck's main U.S. patent for the cancer treatment expires in 2028, opening the ...

Merck ( MRK) reported fourth quarter and full-year earnings Tuesday, in line with Wall Street estimates. The bad news: Its ...

put both stocks in the category of "cheap" to buy for now but with positive long-term potential. Merck's two big revenue products are its HPV vaccine, Gardasil, and cancer drug Keytruda.

The TSX parent reported adjusted earnings per share of 48 cents, topping the Street’s expectation by 4 cents as organic ...

Pyxis Oncology announces Phase 1/2 trials for PYX-201, combining it with KEYTRUDA® to treat advanced solid tumors. Pyxis Oncology, Inc. has announced the initiation of two significant clinical ...